The quarter was a non-event operationally — the narrower loss was entirely cost-driven, not revenue growth. The stock will trade on EDIT-401 clinical catalysts: IND/CTA submission by mid-2026 and first human proof-of-concept data by year-end 2026. Monitor for any delays in these milestones or additional financing needs given the $123.6M cash balance.
Price Chart
Executive Summary
Editas Medicine reported Q1 2026 results with a net loss of $0.26 per share, narrower than the $0.92 loss in Q1 2025, driven by significant cost reductions from the discontinued reni-cel program. Collaboration revenue fell to $2.8M from $4.7M, and cash burn continued with cash dropping to $123.6M from $146.6M at year-end 2025. The PTAB reaffirmed the Broad Institute's CRISPR-Cas9 patent position, a neutral legal development for the company's licensed IP.
Key Financial Metrics
Key Facts
- Net loss per share improved to -$0.26 from -$0.92 YoY, driven by a 66% reduction in operating expenses
- Collaboration revenue declined 39% YoY to $2.8M as prior-year partner milestones concluded
- Cash and equivalents fell to $123.6M, down from $146.6M at Dec 2025; runway guided into Q3 2027
- EDIT-401 IND/CTA submission on track for mid-2026 with first-in-human trial initiation expected later this year
- PTAB reaffirmed Broad Institute's CRISPR-Cas9 patent position for the third time; CVC retains appeal rights
- No restructuring charges in Q1 2026 vs $40.9M in Q1 2025, reflecting completion of reni-cel wind-down
Financial Impact
Net loss improved by $51.1M YoY to -$25.0M; cash burn of $23.0M in Q1 2026
Risk Factors
- Cash runway only into Q3 2027; may require dilutive financing before EDIT-401 data readout
- EDIT-401 is still preclinical; clinical failure or regulatory delays would reset the investment thesis
- CVC may appeal PTAB decision, creating long-term patent uncertainty for the licensed Cas9 IP
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001650664-26-000043 |
| Document: edit-20260505.htm | 0001650664-26-000043 |
| Document: 0001650664-26-000043-index-headers.html | 0001650664-26-000043 |
| Document: 0001650664-26-000043-index.html | 0001650664-26-000043 |
| Document: 0001650664-26-000043.txt | 0001650664-26-000043 |
| 8-K Data (Synthetic) | 0001650664-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.84 | awaiting T+20 | — | $2.40 (−15.49%) |
Sep 9, 2026 6w ago | EFFECT | $2.77 $2.75 | ▼ −0.72% | ▼ −2.92% | $2.40 (−13.36%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.44 $3.30 | ▲ +35.25% | ▲ +33.35% | $2.40 (−1.64%) |
May 26, 2026 21w ago | 424B5 | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | 8-K | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | 8-K | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
May 26, 2026 21w ago | 424B5 | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers